ES2505090T3 - Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer - Google Patents
Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer Download PDFInfo
- Publication number
- ES2505090T3 ES2505090T3 ES05779977.7T ES05779977T ES2505090T3 ES 2505090 T3 ES2505090 T3 ES 2505090T3 ES 05779977 T ES05779977 T ES 05779977T ES 2505090 T3 ES2505090 T3 ES 2505090T3
- Authority
- ES
- Spain
- Prior art keywords
- nr13r13
- nr13c
- halo
- nr13r14
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuesto de fórmula I: y sales farmaceuticamente aceptables del mismo, en la que A es N o CR13; B es N o CR11; D es CR12; E es N; G es NR13, 0, S, C(0), S(0), SO2, CR13R13 o CR 13R14; H1 es N o CR5; H2 es N o CR6; H3 es CR7; H4 es CR8; H5 es N o CR9; R1 es H, halo, haloalquilo, NO2, CN, NR13R13, 0rl'-`13, SR13, (CHR13)nR13 o R15; alternativamente R1 tornado junto con R13 forma un anillo de atomos de carbono parcial o completamente insaturado de 5 0 6 miembros que incluye opcionalmente 1-3 heteroatomos seleccionados de 0, N y S, y estando el anillo opcionalmente sustituido independientemente con 1-3 sustituyentes de R13, halo, haloalquilo, oxo, NO2, CN, SR13, OR13, OC(0)R13, C00R13, C(0)R13, C(0)NR13R13, NR13R13, NR13R14 0 NR14R14; R2 es H, halo, NO2, CN, alquilo C1-10 o alcoxilo C1-10; cada uno de R3 v R4 es independientemente H, halo, haloalquilo, oxo, NO2, CN, SR13 OR13, NR13R13, NR13R14, C(0)R3, C00R13, OC(0)R13, C(0)C(0)R13, C(0)NR13R13, C(0)NR13R14, NR13c(o)R13, NR13C(9R14, NR13C(30)NR13R13 ' NR13C(0)C(0)R13 NR I3(COOR13), OC(0)NR13R13, S(0)2R13, S(0)2NR 3R1, NR1 S(0)2NR131R13, NR S(0)2R 13, NR 13 S(0)2R14, NR13C(0)C(0)NRI3R13, 25 NR1jC(0)C(0)NR13 r(,-,14, alquilo C1_10, alquenilo C1_10, alquinilo C1_10, cicloalquilo C3-8 o cicloalquenilo C4-8, en los que el alquilo C1_10, alquenilo C1_10, alquinilo C1_10, cicloalquilo C3-8 y cicloalquenilo C4-8 estan opcionalmente sustituidos independientemente con uno o mas sustituyentes de R13; alternativamente, cualquiera de R3 o R4 independientemente tornado junto con R12 forma un anillo de atomos de carbono parcial o completamente insaturado de 5 0 6 miembros que incluye opcionalmente 1-3 heteroatomos seleccionados de 0, N o S, y estando el anillo opcionalmente sustituido independientemente con 1-3 sustituyentes de R13.
Description
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 imagen7 imagen8 imagen9 imagen10 imagen11 imagen12 imagen13 imagen14 imagen15 imagen16 imagen17 imagen18 imagen19 imagen20 imagen21 imagen22 imagen23 imagen24 imagen25 imagen26 imagen27 imagen28 imagen29 imagen30 imagen31 imagen32 imagen33 imagen34 imagen35 imagen36 imagen37 imagen38 imagen39
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56919304P | 2004-05-07 | 2004-05-07 | |
| US569193P | 2004-05-07 | ||
| PCT/US2005/016346 WO2005113494A2 (en) | 2004-05-07 | 2005-05-09 | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2505090T3 true ES2505090T3 (es) | 2014-10-09 |
Family
ID=35149480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05779977.7T Expired - Lifetime ES2505090T3 (es) | 2004-05-07 | 2005-05-09 | Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7880000B2 (es) |
| EP (1) | EP1751136B1 (es) |
| JP (1) | JP5097539B2 (es) |
| AU (1) | AU2005245386B2 (es) |
| CA (1) | CA2564355C (es) |
| ES (1) | ES2505090T3 (es) |
| MX (1) | MXPA06012613A (es) |
| WO (1) | WO2005113494A2 (es) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050165031A1 (en) * | 2003-11-13 | 2005-07-28 | Ambit Biosciences Corporation | Urea derivatives as ABL modulators |
| TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| EP1751136B1 (en) * | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| AU2011253934C1 (en) * | 2004-06-17 | 2013-08-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| WO2006009726A2 (en) | 2004-06-17 | 2006-01-26 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| KR20160058972A (ko) * | 2004-09-02 | 2016-05-25 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| JP2008523072A (ja) * | 2004-12-07 | 2008-07-03 | ルーカス ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| JP2008523071A (ja) * | 2004-12-07 | 2008-07-03 | ルーカス ファーマシューティカルズ， インコーポレイテッド | Ｍａｐキナーゼの尿素インヒビター |
| US7470693B2 (en) * | 2005-04-21 | 2008-12-30 | Bristol-Myers Squibb Company | Oxalamide derivatives as kinase inhibitors |
| RU2435769C2 (ru) * | 2005-05-20 | 2011-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиридины, полезные в качестве ингибиторов протеинкиназы |
| WO2007035428A1 (en) * | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| US7576102B2 (en) * | 2005-12-21 | 2009-08-18 | Decode Genetics Ehf | Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation |
| AU2011211423B2 (en) * | 2005-12-23 | 2014-02-20 | Amgen Inc. | Nitrogen-containing bicyclic hetroaryl compounds for the treatment of RAF protein kinase-mediated diseases |
| US7989461B2 (en) * | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| CA2635888A1 (en) * | 2006-01-04 | 2007-07-19 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| MY161884A (en) * | 2006-01-23 | 2017-05-15 | Amgen Inc | Aurora kinase modulators and method of use |
| US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| KR20080092412A (ko) * | 2006-02-06 | 2008-10-15 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| WO2007146981A2 (en) * | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha |
| TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| FR2904626B1 (fr) | 2006-08-03 | 2008-09-19 | Sanofi Aventis | Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique |
| US7683060B2 (en) | 2006-08-07 | 2010-03-23 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| EP1894928A1 (en) * | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
| US8236823B2 (en) * | 2006-10-27 | 2012-08-07 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| CA2669266C (en) * | 2006-11-08 | 2014-04-29 | Bristol-Myers Squibb Company | Pyridinone compounds |
| GEP20125658B (en) | 2006-11-22 | 2012-10-10 | Incyte Corp | Imidazotriazines and imidazo pyrimidines as kinase inhibitors |
| WO2008079933A2 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
| MX2009010696A (es) * | 2007-04-06 | 2009-10-20 | Novartis Ag | Derivados de 2,6-naftiridina como moduladores de cinasa de proteina. |
| TWI433677B (zh) | 2007-06-04 | 2014-04-11 | Avila Therapeutics Inc | 雜環化合物及其用途 |
| CA2689092C (en) * | 2007-06-07 | 2013-01-15 | Amgen Inc. | Raf kinase modulators and methods of use |
| CA2708613A1 (en) * | 2007-12-10 | 2009-06-18 | Metaproteomics, Llc | Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith |
| EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| HRP20130040T1 (hr) * | 2008-01-23 | 2013-02-28 | Bristol-Myers Squibb Company | 4-piridinon spojevi i njihova uporaba kod karcinoma |
| WO2009094427A1 (en) | 2008-01-23 | 2009-07-30 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
| GB0801416D0 (en) * | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| HRP20170317T1 (hr) * | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| CN103936743B (zh) | 2008-05-21 | 2018-04-24 | 因西特控股公司 | 2-氟-N-甲基-4-[7-(喹啉-6-基甲基)咪唑并[1,2-b][1,2,4]三嗪-2-基]苯甲酰胺的盐及与其相关的制备方法 |
| JP2012501188A (ja) * | 2008-08-29 | 2012-01-19 | ジェネンテック， インコーポレイテッド | Ｖｅｇｆ非依存性腫瘍についての診断薬および治療 |
| WO2010033655A1 (en) * | 2008-09-19 | 2010-03-25 | Complegen, Inc. | Compounds and methods for pkc theta inhibition |
| NZ592993A (en) * | 2008-10-22 | 2013-02-22 | Acucela Inc | Compounds for treating ophthalmic diseases and disorders |
| KR101052066B1 (ko) | 2008-10-24 | 2011-07-27 | 한국과학기술연구원 | 항암 활성을 갖는 신규한 6-(피리딘-3-일)피리미딘 화합물 |
| CN101759683B (zh) * | 2008-12-25 | 2011-12-28 | 哈尔滨誉衡药业股份有限公司 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| CN102548987B (zh) * | 2009-07-14 | 2014-04-16 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的氟取代化合物及其使用方法 |
| EA025304B1 (ru) | 2010-02-03 | 2016-12-30 | Инсайт Холдингс Корпорейшн | ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ |
| CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| EP2647637B1 (en) * | 2010-12-02 | 2016-02-03 | Medpacto Inc. | Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient |
| CN103018349B (zh) * | 2011-09-22 | 2015-04-08 | 北京美迪康信医药科技有限公司 | 一种二氢化茚酰胺化合物的检测分析方法 |
| RU2486180C1 (ru) * | 2011-11-02 | 2013-06-27 | Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") | Способ получения 2-ариламино-4-гетарилпиримидинов |
| PE20141370A1 (es) * | 2011-12-09 | 2014-10-17 | Chiesi Farma Spa | Inhibidores de quinasa |
| KR101415742B1 (ko) * | 2011-12-21 | 2014-07-04 | 영남대학교 산학협력단 | 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| CN102807558A (zh) * | 2012-08-29 | 2012-12-05 | 浙江大德药业集团有限公司 | 作为蛋白激酶抑制剂的含氟二氢化茚酰胺类化合物 |
| ES2858511T3 (es) * | 2012-10-17 | 2021-09-30 | Exonate Ltd | Compuestos útiles para tratar neovascularización ocular |
| KR20140092696A (ko) * | 2013-01-16 | 2014-07-24 | 주식회사유한양행 | 신규의 페닐에티닐 벤즈아마이드 글루코키나제 활성화제 및 그의 제조방법 |
| US10179781B2 (en) | 2013-03-15 | 2019-01-15 | Chromocell Corporation | Sodium channel modulators for the treatment of pain |
| CA2916653C (en) | 2013-06-27 | 2017-07-18 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| EP3043787B1 (en) | 2013-09-10 | 2018-09-05 | Chromocell Corporation | Sodium channel modulators for the treatment of pain and diabetes |
| EP3083604A1 (en) | 2013-12-20 | 2016-10-26 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| CN104045632B (zh) * | 2014-06-03 | 2016-09-07 | 辽宁大学 | 抗肿瘤药物苯并二氢吡喃（噻喃）酰胺类化合物及其药学上可接受的盐及制备方法和应用 |
| AU2016209321B2 (en) * | 2015-01-20 | 2019-05-09 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic compounds, compositions and method of using thereof |
| WO2017044434A1 (en) * | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| KR20180052635A (ko) * | 2015-09-18 | 2018-05-18 | 가켄 세이야쿠 가부시키가이샤 | 바이아릴 유도체 및 이를 포함하는 약제 |
| AR111281A1 (es) | 2017-03-17 | 2019-06-26 | Genentech Inc | Compuestos de pirimidinil-piridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 |
| CA3074641A1 (en) * | 2017-09-07 | 2019-03-14 | Augusta University Research Institute, Inc. | Specific akt3 activator and uses thereof |
| US12391669B2 (en) | 2018-08-30 | 2025-08-19 | The Regents of the University of California et al. | Substituted pyrimidines as IRE1 kinase inhibitors |
| TWI831829B (zh) * | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| JP7098826B2 (ja) * | 2018-09-12 | 2022-07-11 | ジェネンテック， インコーポレイテッド | ピリミジニル－ヘテロアリールオキシ－ナフチル化合物および使用方法 |
| WO2020142612A1 (en) | 2019-01-03 | 2020-07-09 | Genentech, Inc. | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
| EP3917526A4 (en) | 2019-01-29 | 2022-11-02 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| KR102878873B1 (ko) * | 2019-02-14 | 2025-10-31 | 브리진 바이오사이언시스, 인코포레이티드 | 암 치료를 위한 fgfr 억제제 |
| AR118119A1 (es) | 2019-02-18 | 2021-09-22 | Genentech Inc | Compuestos de pirido-pirimidinilo y métodos de uso |
| JP7765972B2 (ja) | 2019-06-11 | 2025-11-07 | ジェネンテック， インコーポレイテッド | キナゾリニル化合物及び使用方法 |
| US20220306640A1 (en) * | 2019-09-06 | 2022-09-29 | Ono Pharmaceutical Co., Ltd. | Hydantoin derivative |
| WO2021155225A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN116322780A (zh) * | 2020-07-29 | 2023-06-23 | 福宏治疗公司 | 化合物及其用途 |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| CN115843296B (zh) * | 2020-08-07 | 2024-03-08 | 南京迈晟科技有限责任公司 | Cdk9抑制剂及其用途 |
| EP3995494B1 (en) * | 2020-11-06 | 2025-06-18 | Eberhard Karls Universität Tübingen | Protein-protein interaction modulators of aurora kinase a and their use in the prevention and/or treatment of cancer |
| KR20230118855A (ko) * | 2020-11-13 | 2023-08-14 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | IRE1α 억제제 및 이의 용도 |
| US20240262803A1 (en) * | 2021-03-24 | 2024-08-08 | Chungdu Anticancer Bioscience Ltd | Compounds, compositions and methods of treating disorders |
| WO2023283263A1 (en) | 2021-07-06 | 2023-01-12 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| CA3236920A1 (en) * | 2021-11-05 | 2023-05-11 | Georgiamune Inc. | Akt3 modulators |
| WO2023183444A1 (en) * | 2022-03-24 | 2023-09-28 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
| WO2024129896A1 (en) * | 2022-12-14 | 2024-06-20 | The Regents Of The University Of California | Inhibitors of procaspase-6 activation and uses thereof |
| WO2024129892A2 (en) * | 2022-12-14 | 2024-06-20 | The Regents Of The University Of California | Inhibitors of procaspase-6 activation and uses thereof |
| EP4661966A1 (en) * | 2023-02-06 | 2025-12-17 | Type6 Therapeutics, Inc. | Compounds, compositions, and methods of use thereof |
| WO2024196961A2 (en) * | 2023-03-21 | 2024-09-26 | Type6 Therapeutics, Inc. | Cdk2 modulators, compositions, and methods of use thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA80492B (en) * | 1979-02-07 | 1981-01-28 | Hoffmann La Roche | Benzazepine derivatives |
| US4318854A (en) * | 1979-02-07 | 1982-03-09 | Hoffmann-La Roche Inc. | Intermediates in the production of 2-benzazepines |
| FR2450833A1 (fr) * | 1979-02-07 | 1980-10-03 | Hoffmann La Roche | Derives de benzazepine |
| JPS6094964A (ja) * | 1983-10-31 | 1985-05-28 | Banyu Pharmaceut Co Ltd | 置換−２−ピリドン誘導体 |
| US5049570A (en) * | 1990-01-23 | 1991-09-17 | Du Pont Merck Pharmaceutical Company | Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity |
| US5506227A (en) | 1992-04-13 | 1996-04-09 | Merck Frosst Canada, Inc. | Pyridine-substituted benzyl alcohols as leukotriene antagonists |
| EP0860433B1 (en) * | 1995-11-07 | 2002-07-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
| JPH11209350A (ja) * | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| ES2306671T3 (es) * | 1999-10-07 | 2008-11-16 | Amgen Inc. | Inhibidores de triazina quinasa. |
| HK1054033A1 (zh) | 2000-08-08 | 2003-11-14 | Ortho-Mcneil Pharmaceutical, Inc. | 4-嘧啶胺衍生物、药用组合物和相关方法 |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| WO2002032872A1 (fr) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Composes a noyau aromatique azote |
| HUP0400639A3 (en) * | 2000-12-21 | 2010-03-29 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them |
| CA2439263C (en) * | 2001-03-02 | 2012-10-23 | Frank Becker | Three hybrid assay system |
| US6864255B2 (en) * | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
| WO2002083628A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused compounds |
| KR100883731B1 (ko) | 2001-06-22 | 2009-02-12 | 기린 파마 가부시끼가이샤 | 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물 |
| US7122543B2 (en) * | 2001-09-17 | 2006-10-17 | Daiichi Suntory Pharma Co., Ltd. | Substituted benzoic acid derivatives having NF-κB inhibiting action |
| CA2463822A1 (en) | 2001-11-01 | 2003-05-08 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| US20040039601A1 (en) * | 2002-08-23 | 2004-02-26 | Anderson Corey D. | Virtual file cabinet including health information method and apparatus |
| CA2520323C (en) | 2003-04-09 | 2013-07-09 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| EP1678147B1 (en) * | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| JP2007507531A (ja) * | 2003-09-30 | 2007-03-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| US7608639B2 (en) * | 2003-10-14 | 2009-10-27 | Eli Lilly And Company | Phenoxyether derivatives as PPAR modulators |
| EP1751136B1 (en) * | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| US7989461B2 (en) * | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US7560551B2 (en) * | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
-
2005
- 2005-05-09 EP EP05779977.7A patent/EP1751136B1/en not_active Expired - Lifetime
- 2005-05-09 WO PCT/US2005/016346 patent/WO2005113494A2/en not_active Ceased
- 2005-05-09 US US11/126,000 patent/US7880000B2/en active Active
- 2005-05-09 ES ES05779977.7T patent/ES2505090T3/es not_active Expired - Lifetime
- 2005-05-09 CA CA2564355A patent/CA2564355C/en not_active Expired - Lifetime
- 2005-05-09 AU AU2005245386A patent/AU2005245386B2/en not_active Expired
- 2005-05-09 MX MXPA06012613A patent/MXPA06012613A/es active IP Right Grant
- 2005-05-09 JP JP2007511723A patent/JP5097539B2/ja not_active Expired - Lifetime
-
2010
- 2010-11-22 US US12/952,156 patent/US8476434B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2564355C (en) | 2012-07-03 |
| JP2007536280A (ja) | 2007-12-13 |
| US20110201602A1 (en) | 2011-08-18 |
| WO2005113494A2 (en) | 2005-12-01 |
| EP1751136B1 (en) | 2014-07-02 |
| CA2564355A1 (en) | 2005-12-01 |
| EP1751136A2 (en) | 2007-02-14 |
| US20060009453A1 (en) | 2006-01-12 |
| AU2005245386B2 (en) | 2008-11-27 |
| MXPA06012613A (es) | 2007-01-31 |
| US8476434B2 (en) | 2013-07-02 |
| US7880000B2 (en) | 2011-02-01 |
| WO2005113494A3 (en) | 2006-03-16 |
| JP5097539B2 (ja) | 2012-12-12 |
| AU2005245386A1 (en) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2505090T3 (es) | Derivados heterocíclicos nitrogenados como moduladores de proteína cinasas y su uso para el tratamiento de angiogénesis y cáncer | |
| ES2502790T3 (es) | Moduladores de la cinasa Aurora y método de uso | |
| PE20110805A1 (es) | Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso | |
| PE20071328A1 (es) | Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso | |
| AR060591A1 (es) | Compuestos imidazo | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| CL2007001555A1 (es) | Compuestos derivados de 4-amino-pirido[3,2-e]pirazinas; inhibidores de fosfodiesterasa 10 (pde10); procedimeinto de preparacion; composicion framaceutica; combinacion farmaceutica, y sus uso en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y otros trastornos psicoticos. | |
| AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
| AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
| BRPI0607762B8 (pt) | análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto | |
| CO5700754A2 (es) | Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas | |
| AR068813A1 (es) | Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata | |
| ES2570745T3 (es) | Aza-heterociclos bicíclicos y su uso | |
| CL2011002706A1 (es) | Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras. | |
| NI201000011A (es) | Derivados de pirimidina 934. | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| PE20040373A1 (es) | Composiciones herbicidas que comprenden derivados de isoxazolina | |
| CL2011001389A1 (es) | Compuestos derivados de isoxazolina; composicion que comprende a uno de los compuestos; y uso de los compuestos en el control de parasitos. | |
| CO6251271A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| AR076753A1 (es) | Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides. | |
| AR060732A1 (es) | Usos del escitalopram | |
| AR063028A1 (es) | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. | |
| CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| SV2007002397A (es) | Aminopiridinas como inhibidores de b-secretasa ref. am101663 |